IFNG and neoplasm: When MPN/CpG is combined with the OVA antigen to form a tumor vaccine, the vaccine induces a strong specific cellular and humoral immune response, showing the highest activation of OVA‐specific T cells, IFN‐γ+CD8+ T cells, and IgG antibody secretion.